361 Capital LLC Invests $1.60 Million in Ionis Pharmaceuticals, Inc. (IONS)

361 Capital LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 31,366 shares of the company’s stock, valued at approximately $1,596,000.

Other institutional investors have also recently made changes to their positions in the company. UBS Asset Management Americas Inc. grew its stake in Ionis Pharmaceuticals by 3.5% in the first quarter. UBS Asset Management Americas Inc. now owns 318,360 shares of the company’s stock valued at $12,798,000 after purchasing an additional 10,877 shares during the last quarter. Karp Capital Management Corp purchased a new position in Ionis Pharmaceuticals in the first quarter valued at about $687,000. Parametric Portfolio Associates LLC grew its stake in Ionis Pharmaceuticals by 8.4% in the first quarter. Parametric Portfolio Associates LLC now owns 99,863 shares of the company’s stock valued at $4,014,000 after purchasing an additional 7,776 shares during the last quarter. Prudential Financial Inc. grew its stake in Ionis Pharmaceuticals by 36.4% in the first quarter. Prudential Financial Inc. now owns 8,241 shares of the company’s stock valued at $331,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Westpac Banking Corp purchased a new position in Ionis Pharmaceuticals in the first quarter valued at about $171,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

IONS has been the topic of several analyst reports. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Wednesday, July 12th. Stifel Nicolaus reiterated a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, September 12th. BMO Capital Markets reiterated an “outperform” rating and issued a $62.00 target price (up previously from $59.56) on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 25th. Finally, Barclays PLC initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $49.44.

WARNING: “361 Capital LLC Invests $1.60 Million in Ionis Pharmaceuticals, Inc. (IONS)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/11/361-capital-llc-invests-1-60-million-in-ionis-pharmaceuticals-inc-ions.html.

In other news, SVP C Frank Bennett sold 10,000 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock worth $4,411,650. Company insiders own 1.86% of the company’s stock.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down 0.278% during midday trading on Wednesday, reaching $55.685. The company’s stock had a trading volume of 87,514 shares. The stock’s 50-day moving average price is $53.78 and its 200-day moving average price is $49.38. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. The company has a market cap of $6.92 billion, a P/E ratio of 265.167 and a beta of 3.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter in the previous year, the company posted ($0.47) EPS. The company’s revenue was up 170.7% compared to the same quarter last year. On average, analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmac

Other institutional investors have also recently made changes to their positions in the company. UBS Asset Management Americas Inc. grew its stake in Ionis Pharmaceuticals by 3.5% in the first quarter. UBS Asset Management Americas Inc. now owns 318,360 shares of the company’s stock valued at $12,798,000 after purchasing an additional 10,877 shares during the last quarter. Karp Capital Management Corp purchased a new position in Ionis Pharmaceuticals in the first quarter valued at about $687,000. Parametric Portfolio Associates LLC grew its stake in Ionis Pharmaceuticals by 8.4% in the first quarter. Parametric Portfolio Associates LLC now owns 99,863 shares of the company’s stock valued at $4,014,000 after purchasing an additional 7,776 shares during the last quarter. Prudential Financial Inc. grew its stake in Ionis Pharmaceuticals by 36.4% in the first quarter. Prudential Financial Inc. now owns 8,241 shares of the company’s stock valued at $331,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Westpac Banking Corp purchased a new position in Ionis Pharmaceuticals in the first quarter valued at about $171,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

IONS has been the topic of several analyst reports. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Wednesday, July 12th. Stifel Nicolaus reiterated a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, September 12th. BMO Capital Markets reiterated an “outperform” rating and issued a $62.00 target price (up previously from $59.56) on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 25th. Finally, Barclays PLC initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $49.44.

WARNING: “361 Capital LLC Invests $1.60 Million in Ionis Pharmaceuticals, Inc. (IONS)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/11/361-capital-llc-invests-1-60-million-in-ionis-pharmaceuticals-inc-ions.html.

In other news, SVP C Frank Bennett sold 10,000 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock worth $4,411,650. Company insiders own 1.86% of the company’s stock.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down 0.278% during midday trading on Wednesday, reaching $55.685. The company’s stock had a trading volume of 87,514 shares. The stock’s 50-day moving average price is $53.78 and its 200-day moving average price is $49.38. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. The company has a market cap of $6.92 billion, a P/E ratio of 265.167 and a beta of 3.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter in the previous year, the company posted ($0.47) EPS. The company’s revenue was up 170.7% compared to the same quarter last year. On average, analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply